[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"narcolepsy-with-cataplexy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:narcolepsy-with-cataplexy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100620907","phase-3-a-trial-of-tak-861-for-the-treatment-of-narcolepsy-with-cataplexy-100620907",false,"NCT07363720","A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy","A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)","Inclusion Criteria:\n\n1. The participant has a body mass index (BMI) within the range 18 to 40 kilograms per square meter (kg\u002Fm\\^2).\n2. The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR) diagnosis of NT1.\n3. The participant is positive for the human leukocyte antigen (HLA) genotype Major Histocompatibility Complex, Class II, DQ Beta 1 (HLA-DQB1\\*06:02) or results from radioimmunoassay indicate the participant's CSF OX\u002Fhypocretin-1 concentration is ≤110 pg\u002FmL (or less than one-third of the mean values obtained in normal participants within the same standardized assay).\n\nExclusion Criteria:\n\n1. The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with EDS.\n2. The participant a) has a history of myocardial infarction, b) has a history of clinically significant hepatic disease, thyroid disease, coronary artery disease, cardiac rhythm abnormality or heart failure, or c) has any medical condition (such as unstable cardiovascular, pulmonary, renal or gastrointestinal disease.\n3. The participant has current or recent (within 6 months) gastrointestinal disease that is expected to influence the absorption of drugs.\n4. The participant has a history of cancer in the past 5 years.\n5. The participant has a clinically significant history of head injury or head trauma.\n6. The participant has a history of epilepsy, seizure, or convulsion (except for a single febrile seizure in childhood).\n7. The participant has a history of cerebral ischemia, transient ischemic attack (less than 5 years from screening), intracranial aneurysm, or arteriovenous malformation.","ALL","16 Years","70 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The main aim of this study is to assess how effective TAK-861 is for treating narcolepsy type 1 and if this effect is maintained over time. Participants will take TAK-861 for a few months and if they meet certain criteria, they will be randomly assigned (by chance, like flipping a coin) to continue taking TAK-861 or take placebo (fake medicine) for up to 4 weeks to see if their narcolepsy symptoms return.",[27,28],"Narcolepsy Type 1 (NT1)","Narcolepsy With Cataplexy",[30],"Drug Therapy","RECRUITING","2026-05-07",{"date":34,"type":35},"2026-05-08","ACTUAL",{"date":37,"type":35},"2026-01-29",{"date":39,"type":21},"2026-10-02",{"name":41,"class":42},"Takeda","INDUSTRY",18,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100545584","decreasing-nightmares-in-adults-with-narcolepsy-100545584","NCT06383806","Decreasing Nightmares in Adults With Narcolepsy","Imagery Rehearsal Therapy for the Treatment of Nightmares in Narcolepsy: A Pilot Randomized Controlled Trial","DAWN","PARTICIPANTS WITH NARCOLEPSY\u002FNIGHTMARES\n\nInclusion Criteria:\n\n* Diagnosis of narcolepsy type 1 or narcolepsy type 2\n* Nightmare frequency of ≥1 times per week\n* Age 18 or older\n* Able to speak, read, and write in English\n* Live in the United States\n* Sleep and psychiatric medications stable for ≥ 1 month and willing to keep medications stable for the duration of the study\n\nExclusion Criteria:\n\n* Currently engaged in trauma- or sleep-related psychotherapy\n* Previous behavioral treatment for nightmares\n* Medical, psychiatric, or cognitive condition which would interfere with ability to engage in the treatment\n* Untreated moderate-severe sleep apnea\n\nPARTICIPANTS WHO ARE PARTNERS OF SOMEONE WITH NARCOLEPSY\n\nInclusion Criteria:\n\n* Live with a romantic partner who meets the above criteria and has agreed to participate in the study\n* Age 18 or older\n* Able to speak, read, and write in English\n* Live in the United States","18 Years",{"count":54,"type":21},80,[56],"NA","The purpose of this clinical trial is learn whether a behavioral (non-medication) treatment can reduce nightmares in adults with narcolepsy. All participants will receive the treatment and will complete three assessments. Half of the participants will receive the treatment after the first assessment, and half will receive it after the second assessment. Romantic partners of participants with narcolepsy will also be eligible to enroll in the study. Partners will complete three assessments but will not participate in the treatment.",[59,60,28,61,62,63],"Narcolepsy","Narcolepsy Type 1","Narcolepsy Without Cataplexy","Nightmare","Nightmare Disorder With Associated Other Sleep Disorder",[65,66],"Imagery Rehearsal Therapy","Cognitive Behavioral Therapy for Nightmares","NOT_YET_RECRUITING","2026-03-09",{"date":70,"type":35},"2026-03-10",{"date":72,"type":21},"2026-04-01",{"date":74,"type":21},"2027-09",{"name":76,"class":77},"University of Utah","OTHER",1]